AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Cyclosporine targets PTEN-deficient cancer cells in a highly specific manner
Summary
Rodney Rothstein, Ph.D.
Technology Benefits
Offers a cancer therapeutic that is cancer-specific and minimizes damage to normal cellsOffers a therapeutics agent that specifically targets PTEN-deficient cellsUtilizes a therapeutic agent that is already used in the clinical setting Patent information:Patent (WO/2012/145426)Tech Ventures Reference: IR 2902
Technology Application
Cancer treatment in PTEN-deficient cancersCancer treatment to be used in combination with other cancer therapeuticsResearch tool for studying PTEN-deficient cancers Research tool for studying CypACyclosporine is an immunosuppressive drug, currently used in transplant patients.
Detailed Technology Description
Rodney Rothstein, Ph.D.
Country/Region
USA
For more information, please click Here
